Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.

Pharmacogenomics - 1 Nov 2010

Lin Keh-Ming, Tsou Hsiao-Hui, Tsai I-Ju, Hsiao Mei-Chun, Hsiao Chin-Fu, Liu Chia-Yih, Shen Winston W, Tang Hwa-Sheng, Fang Chun-Kai, Wu Chi-Shin, Lu Shao-Chun, Kuo Hsiang-Wei, Liu Shu Chih, Chan Hsiu-Wen, Hsu Ya-Ting, Tian Jia-Ni, Liu Yu-Li

Abstract excerpt

AIM: Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD). Its metabolism has recently been reported to be mediated through the CYP enzymes 1A2 and 2D6. In our current study, we tested whether genetic polymorphisms in CYP1A2 are associated with the treatment efficacy and side effects of paroxetine. MATERIALS & METHODS: A total of 241 MDD patients who had taken paroxetine continually...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Depressive Disorder, Major

Share to Paroxetine

Share to Pharmacogenetics and Drug Metabolism

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Identifiers

PMID: 21121774
DOI: 10.2217/pgs.10.128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.PMID 21121774Read ↗

Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.Semantic proximity Read ↗

The impact of CYP allelic variation on antidepressant metabolism: a review.Semantic proximity Read ↗

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.Semantic proximity Read ↗

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.Semantic proximity Read ↗

Pharmacogenetics of antidepressant medication intolerance.Semantic proximity Read ↗

Do we need pharmacogenetics to personalize antidepressant therapy?Semantic proximity Read ↗

Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.Semantic proximity Read ↗

Identifying genetic variants associated with side effects of antidepressant treatment: A systematic review.Semantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

Integrating Genetic Variants and Expression Profiles of Pharmacogenes in Treatment- Resistant DepressionSemantic proximity Read ↗

Pharmacogenomics and antidepressant drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.